Skip to main content
Quest Diagnostics

Improving diabetes care with digital retinal exams

White Paper

Duration: 15 min. read

Topics:

Population Health, Management & Operations, Technology & Innovation

For the 114 million Americans who either have diabetes or are on the cusp of developing it, diabetic retinopathy screening is crucial for preventing vision loss and maintaining quality of life. Health plans have the opportunity to encourage compliance with routine retinal imaging, save millions annually, and improve clinical performance measures (HEDIS®) by delivering convenient, efficient, and cost-effective screening to rural, remote, and hard-to-reach populations.

Download
Page Published: January 10, 2022
Page Updated: 24-Aug-2021

Related Content

White Paper
Manage lab spend to lower costs for health plans and employers
Infographic
Improve member satisfaction with lab pricing transparency
Case Study
New member data informs disease management

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.